Physician profile
Michael Bohnert
NPI 1053990804
$1,404.69
in general payments reported to CMS, 2019-2025
11 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $98.00 · 2023: $566 · 2024: $631 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,306.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $555.73 | 2022-2023 | Rinvoq, Skyrizi |
| Genzyme Corporation | $225.20 | 2024 | |
| Novartis Pharmaceuticals Corporation | $130.02 | 2024 | |
| Amgen INC. | $108.12 | 2023 | Otezla |
| Ucb, INC. | $91.51 | 2024 | Bimzelx |
| Janssen Scientific Affairs, LLC | $88.20 | 2024 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.41 | 2024 | Spevigo |
| Lilly USA, LLC | $71.52 | 2025 | Ebglyss |
| Regeneron Healthcare Solutions, INC. | $21.44 | 2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $17.37 | 2025 | Sotyktu |
| Takeda Pharmaceuticals U.S.A., INC. | $14.17 | 2024 | Fruzaqla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bohnert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.